63234 20171117104915.0 doi 10.1097/MD.0000000000000176 sideral 100184 ART-2014-100184 eng Huerva, V. Infliximab for peripheral ulcerative keratitis treatment 2014 Access copy available to the general public Unrestricted Biologic agents such as anti-TNFa have been employed in treatment paradigms for ocular inflammation. Peripheral corneal ulceration (PUK) is a devastating disorder consisting of a crescent-shaped area of destructive inflammation at the margin of the corneal stroma. It is associated with an epithelial defect, the presence of stromal inflammatory cells, and progressive stromal degradation and thinning, leading to ocular perforation and devastating visual loss. Macroulcerative PUK is usually a local manifestation of a systemic vasculitis. In many cases, the disease may be resistant to high doses of systemic corticosteroids and immunosuppressants. Chimeric anti-TNFa has been employed when all other treatments have failed. Isolated cases and short series of cases have been reported. This paper summarizes the available reports on the use, efficacy, and safety of infliximab in the treatment of PUK. info:eu-repo/semantics/openAccess by http://creativecommons.org/licenses/by/3.0/es/ 5.723 2014 MEDICINE, GENERAL & INTERNAL 15 / 154 = 0.097 2014 Q1 T1 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion (orcid)0000-0001-9876-5850 Ascaso, F. J. Universidad de Zaragoza Grzybowski, A. 1004 646 Universidad de Zaragoza Departamento de Cirugía, Ginecología y Obstetricia Oftalmología 93, 26 (2014), e176 [4 pp] Medicine (Baltim.) Medicine (Baltimore) 0025-7974 111065 http://zaguan.unizar.es/record/63234/files/texto_completo.pdf Versión publicada 8405 http://zaguan.unizar.es/record/63234/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:63234 articulos driver 2017-11-16-13:55:02 ARTICLE